Quick Answer
Anika Therapeutics, Inc. reported Cash and Equivalents of $57.48 million for fiscal year 2025.
Anika Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $57.48M | +3.3% |
| 2024 | $55.63M | -19.1% |
| 2023 | $68.74M | -20.4% |
| 2022 | $86.33M | -8.5% |
| 2021 | $94.39M | -1.5% |
| 2020 | $95.82M | -39.1% |
| 2019 | $157.46M | +76.8% |
| 2018 | $89.04M | -33.2% |
| 2017 | $133.26M | +27.8% |
| 2016 | $104.26M | -5.8% |
| 2015 | $110.71M | +10.5% |
| 2014 | $100.16M | +58.1% |
| 2013 | $63.33M | +43.7% |
| 2012 | $44.07M | +23.2% |
| 2011 | $35.78M | +26.9% |
| 2010 | $28.20M | +15.5% |
| 2009 | $24.43M | -43.4% |
| 2008 | $43.19M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $57.99M | -7.0% | +9.1% |
| June 30, 2025 | $53.17M | -15.4% | -0.4% |
| March 31, 2025 | $53.37M | -22.2% | -4.1% |
| December 31, 2024 | $55.63M | -23.7% | -10.8% |
| September 30, 2024 | $62.37M | -11.7% | -0.7% |
| June 30, 2024 | $62.82M | -3.5% | -8.5% |
| March 31, 2024 | $68.63M | -13.9% | -5.8% |
| December 31, 2023 | $72.87M | -15.6% | +3.1% |
- Anika Therapeutics, Inc. showed an increase of +3.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, Anika Therapeutics, Inc.’s cash and equivalents has grown by 33.1% (from $43.19 million to $57.48 million).
- The most recent figure is from Anika Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: